![Michael Pehl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Pehl
Directeur Général chez
ADCendo ApS
Profil
Michael Pehl is Chief Executive Officer & Director at ADCendo ApS since 2021.
Formerly, Mr. Pehl was President, Chief Executive Officer & Director at Immunomedics, Inc. from 2017 to 2019, Chief Executive Officer at AvenCell Europe GmbH, and President-Global Hematology/Oncology at Celgene Corp.
from 2006 to 2017.
Mr. Pehl completed undergraduate education at Ludwig-Maximilians-Universität München.
Postes actifs de Michael Pehl
| Sociétés | Poste | Début |
|---|---|---|
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Directeur Général | 07/07/2021 |
Anciens postes connus de Michael Pehl
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOMEDICS, INC. | Directeur Général | 23/02/2019 |
| CELGENE | Corporate Officer/Principal | 21/08/2017 |
GEMoaB Monoclonals GmbH
 GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Directeur Général | - |
Formation de Michael Pehl
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
61
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Develops drugs for the treatment of cancer | Health Technology |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Health Technology |
GEMoaB Monoclonals GmbH
GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
